Methods for treating inflammatory skin conditions
AssigneeJourney Medical Corporation
InventorsSwati Kulkarni, Bijay Kumar Padhi, Shanvas Alikunju, Rajeev Singh Raghuvanshi, Srinivas Ramchandra Sidgiddi, Anirudh Gautam
Life of this patent
Estimating the term…
Abstract
The present application relates to a method of treating an inflammatory skin condition by administering a pharmaceutical composition comprising a reduced dose of minocycline to a subject in need thereof, wherein said administration provides an effective plasma or interstitial fluid concentration of minocycline for treating the inflammatory skin condition.
Claims39
A method of treating inflammatory lesions and/or erythema of rosacea in a subject in need thereof, comprising:
- administering an oral pharmaceutical composition comprising a body-weight independent dose of about 10 mg to about 40 mg of minocycline to the subject in need thereof,
- wherein administering the oral pharmaceutical composition reduces the severity of inflammatory lesions and/or erythema of rosacea as compared to the severity of inflammatory lesions and/or erythema of rosacea before administering the oral pharmaceutical composition;
- and
- wherein the number of inflammatory lesions is reduced by at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% compared to the number of inflammatory lesions before administering the oral pharmaceutical composition.
A method of treating inflammatory lesions and/or erythema of rosacea in a subject in need thereof, comprising:
- administering an oral pharmaceutical composition comprising a body-weight independent dose of about 10 mg to about 40 mg of minocycline to the subject in need thereof,
- wherein administering the oral pharmaceutical composition results in:
- (i) a maximum plasma concentration (CmaxP) of about 55 ng/ml to about 450 ng/ml minocycline in the subject;
- and
- (ii) an area under the plasma concentration-time curve (AUC0-tP) of about 830 ng*hour/ml to about 4080 ng*hour/ml minocycline in the subject, and
- wherein the number of inflammatory lesions is reduced by at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% compared to the number of inflammatory lesions before administering the oral pharmaceutical composition.
A method of treating inflammatory lesions and/or erythema of rosacea in a subject in need thereof, comprising:
- administering an oral pharmaceutical composition comprising a body-weight independent dose of about 10 mg to about 40 mg of minocycline to the subject in need thereof,
- wherein the oral pharmaceutical composition comprises an immediate release (IR) portion and an extended release (ER) portion,
- wherein the IR portion and the ER portion are combined in a ratio in a range from about 10:90 to about 90:10, and
- wherein the number of inflammatory lesions is reduced by at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% compared to the number of inflammatory lesions before administering the oral pharmaceutical composition.
Dependencies are inferred from the claim text.